Integra Lifesciences Holdings Corp (NASDAQ:IART)
| Market Cap | $1.03B+10.1% |
| Revenue (ttm) | $1.66B+0.8% |
| Net Income | $13.01M+102.6% |
| EPS | $0.17+102.6% |
| Shares Out | 77.80M |
| PE Ratio | 78.96 |
| Forward PE | 5.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 826,614 |
| Open | $13.38 |
| Previous Close | $13.55 |
| Day's Range | $13.16 - $13.79 |
| 52-Week Range | $8.70 - $20.49 |
| Beta | 1.28 |
| Analysts | Buy |
| Price Target | $16.43(+24.00%) |
| Earnings Date | Feb 25, 2027 |
About IART
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Analyst consensus
7 firms rating IART in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$IART stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of IART by members of U.S. Congress
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Jun 18, 2024 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Apr 5, 2024 |
| Josh GottheimerHouse / D | Purchase$1.00K – $15.00K | Oct 16, 2023 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Sep 15, 2023 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Jun 13, 2023 |
| Josh GottheimerHouse / D | Purchase$1.00K – $15.00K | Oct 16, 2020 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | Sep 15, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 10, 2020 |
Recently reported changes in IART holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IART's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IART Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IART Revenue by Segment or Geography
| Specialty Surgery | $304.12M | 73.96% |
| Tissue Reconstruction | $107.06M | 26.04% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IART patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IART from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IART
| IJRiShares Core S&P Small-Cap ETF | $53.96M |
| IWMiShares Russell 2000 ETF | $24.02M |
| VTIVanguard Morningstar Total Stock Market ETF | $21.09M |
| VBVanguard Morningstar Small-Cap ETF | $18.93M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $15.38M |
| VBRVanguard Morningstar Small-Cap Value ETF | $12.27M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from IART’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XHE | State Street SPDR S&P Health Care Equipment ETF | 1.34% |
| IBRN | iShares Neuroscience and Healthcare ETF | 1.05% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 1.05% |
| NIXT | Research Affiliates Deletions ETF | 0.60% |
| VFLQ | Vanguard U.S. Liquidity Factor ETF | 0.55% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.51% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.49% |
| FYT | First Trust Small Cap Value AlphaDEX Fund | 0.21% |
| SQLV | Royce Quant Small-Cap Quality Value ETF | 0.21% |
| EES | WisdomTree U.S. SmallCap Fund | 0.20% |
| VVL.TO | Vanguard Global Value Factor ETF | 0.19% |
| DMRM | DeltaShares S&P 400 Managed Risk ETF | 0.19% |
Weight is the stock’s share of each fund’s holdings.
